Barclays analyst Gena Wang lowered the firm’s price target on 4D Molecular (FDMT) to $38 from $45 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular Therapeutics Reports Increased Quarterly Loss
- 4D Molecular reports Q1 EPS (86c), consensus (86c)
- 4D Molecular reports Q1 EPS (86c), consensus (83c)
- 4D Molecular sees cash, equivalents funding planned operations into 2028
- 4D Molecular announces RMAT designation granted by FDA for 4D-150 for DME